Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Just 2% of patients on MK-0616 discontinued treatment due to adverse events, compared to 1% of the placebo group. A key advantage for Merck’s drug is that it could slot into therapy alongside ...

Oatly Group AB (Nasdaq: OTLY) has announced plans to change the ratio of its American Depositary Receipts (ADRs) to ordinary shares. Currently, one ADR represents one ordinary share. After the change, ...